Assort Health announced that it has raised $120 million in Series C funding to scale its AI agents platform for the patient journey. The round was led by Menlo Ventures at a $1.2 billion valuation.
Assort Health has now raised more than $222 million to help healthcare organizations transform patient access and administrative workflows with AI.
Additional investors in the latest round included Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.
Assort Health said its platform has supported more than 190 million patient voice interactions to date.
The company’s AI agents platform spans scheduling, intake forms, referrals, document processing, medication refills, real-time eligibility, lab requests, and payments.
Assort said its platform is built on more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating a proprietary specialty healthcare dataset.
The company’s proprietary AI model, Synapse, learns the patterns of specialty workflows across deployments and generates the edge cases, tests, and simulations each workflow must handle.
Assort said its revenue has grown 20x over the past 15 months.
The platform includes Concierge, Activate, Orchestrate, and Empower. These products handle inbound calls, triage, lab requests, medication refills, scheduling, insurance eligibility, intake, referral loops, care gap closure, payments, document processing, and staff AI copilot workflows.
All four products are connected by Patient Journey Memory, which creates a continuous record for each patient and supports personalized experiences across interactions.
Assort also announced a major expansion into health system operations. The company said it is bringing its AI-powered patient access deployment to health systems ranging from large community-based organizations to academic medical centers.
Several health systems, including John Muir Health, are partnering with Assort as demand grows for platforms that can support complex ambulatory operations.
JP Sanday, Partner at Menlo Ventures, will join Assort’s Board, and Matt Murphy, Partner at Menlo Ventures, will serve as a Board Observer.
KEY QUOTES:
“After investing in Anthropic, our thesis was simple: find the best application-layer companies in every category. The value of Assort’s platform compounds with every patient interaction. Each one surfaces a new edge case and a new way to improve care, and the platform gets better for the next patient, automatically. That is a structural advantage that grows with scale, and it lets Assort deliver outsized value for every customer in a way other platforms simply haven’t matched.”
Matt Murphy, Partner at Menlo Ventures
“Every so often a company comes along that fundamentally reimagines how an industry operates. Assort is that company for healthcare. They’ve built not just another point solution, but a unified platform of AI agents that elevates the entire patient journey. Assort’s customer-obsessed approach and exceptional product velocity position them to lead the AI transformation of the multi-trillion-dollar healthcare industry, which is why the best healthcare groups keep working with Assort.”
JP Sanday, Partner at Menlo Ventures
“When a patient reaches out for care, you often get one chance to earn their trust. A mishandled interaction doesn’t just create operational problems; it can mean losing that patient altogether. That’s why we wanted a partner with a proven track record of handling specialty care complexity at scale. Assort’s experience across hundreds of deployments gave us confidence they could deliver from day one, and they’ve helped us ensure patients move through the right care journey from their very first interaction.”
Jon Shaker, Executive Director of Boston Bone and Joint Institute
“We evaluated every AI solution on the market. Assort was the only true platform. It runs the full patient journey as one connected system, from referrals and document processing to intake, care gap closure, real-time eligibility, and payments. The difference is memory. Everyone else automates one piece and forgets the rest. Assort remembers every patient across every interaction and connects it all into one conversation. Our automation rate climbs every quarter as they execute against an ambitious roadmap, and the gap between Assort and everyone else keeps widening.”
Dr. Parinita Amin, CEO of MDCS Dermatology
“This market is going to consolidate in the same way every other one has. Provider groups know it, and the smart ones aren’t buying another point solution. They want one partner with the capital and the engineering depth to transform how they operate over the long run. That’s what we built. Our engineers learn across hundreds of customers and build every implementation for the specific practice in front of them, and we have now raised over $220M to make that engine better.”
Jon Wang, Founder and Co-CEO of Assort Health
“Specialty care is a different discipline than most AI vendors realize, and that difficulty only compounds at large health systems. It’s exactly what we built Synapse for. Our proprietary model learns the patterns of specialty workflows and gets sharper with every deployment, and that’s what lets us move past answering calls to automating the entire patient journey. That depth is our advantage, and Synapse is the foundation that lets us build faster than anyone in the market.”
Jeffery Liu, Founder and Co-CEO of Assort Health
